These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 34231442)
61. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
62. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. Meece J Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986 [TBL] [Abstract][Full Text] [Related]
63. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Lamos EM; Malek R; Davis SN Expert Rev Clin Pharmacol; 2017 Apr; 10(4):401-408. PubMed ID: 28276778 [TBL] [Abstract][Full Text] [Related]
64. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884 [TBL] [Abstract][Full Text] [Related]
65. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302 [TBL] [Abstract][Full Text] [Related]
66. Semaglutide for the treatment of obesity. Chao AM; Tronieri JS; Amaro A; Wadden TA Trends Cardiovasc Med; 2023 Apr; 33(3):159-166. PubMed ID: 34942372 [TBL] [Abstract][Full Text] [Related]
67. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008 [TBL] [Abstract][Full Text] [Related]
69. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047 [TBL] [Abstract][Full Text] [Related]
74. GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials. Smits MM; Ten Kulve JS; van Bloemendaal L; Tonneijck L; Muskiet MHA; Kramer MHH; Ijzerman RG; van Raalte DH Nutrition; 2019; 67-68():110524. PubMed ID: 31415908 [TBL] [Abstract][Full Text] [Related]
75. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. Gomez-Peralta F; Abreu C Drug Des Devel Ther; 2019; 13():731-738. PubMed ID: 30863012 [TBL] [Abstract][Full Text] [Related]
76. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276 [TBL] [Abstract][Full Text] [Related]
77. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. Page LC; Freemark M Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056 [TBL] [Abstract][Full Text] [Related]
79. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761 [TBL] [Abstract][Full Text] [Related]
80. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials. Costantino S; Paneni F Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]